How Common Are Myeloproliferative Neoplasms? A Systematic Review and Meta-analysis
Overview
Authors
Affiliations
Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including polycythemia vera (PV), essential thrombocythemia (ET), and primary(idiopathic) myelofibrosis (PMF). In this systematic review, we provide a comprehensive report on the incidence and prevalence of MPNs across the globe. Electronic databases (PubMed, EMBASE, MEDLINE, and Web of Science) were searched from their inception to August 2012 for articles reporting MPN incidence or prevalence rates. A random effects meta-analysis was undertaken to produce combined incidence rates for PV, ET, and PMF. Both heterogeneity and small study bias were assessed. Thirty-four studies were included. Reported annual incidence rates ranged from 0.01 to 2.61, 0.21 to 2.27, and 0.22 to 0.99 per 100,000 for PV, ET, and PMF, respectively. The combined annual incidence rates for PV, ET, and PMF were 0.84, 1.03, and 0.47 per 100,000. There was high heterogeneity across disease entities (I(2) 97.1-99.8%) and evidence of publication bias for ET and PMF (Egger test, P = 50.007 and P ≤ 0.001, respectively).The pooled incidence reflects the rarity of MPNs. The calculated pooled incidence rates do not reflect MPN incidence across the globe due to the high unexplained heterogeneity. Improved, widespread registration of MPNs would provide better information for global comparison of the incidence and prevalence of MPNs.
Passamonti F, Korgaonkar S, Parikh R, Chevli M, Yucel A, Rombi J Future Oncol. 2025; 21(5):579-591.
PMID: 39865562 PMC: 11845104. DOI: 10.1080/14796694.2025.2454895.
Lagana A, Scalzulli E, Carmosino I, Bisegna M, Martelli M, Breccia M Oncol Ther. 2025; 13(1):165-183.
PMID: 39821749 PMC: 11880497. DOI: 10.1007/s40487-024-00322-2.
Wang Y, Fei Y Medicine (Baltimore). 2024; 103(51):e40945.
PMID: 39705412 PMC: 11666147. DOI: 10.1097/MD.0000000000040945.
Investigational drugs in early phase trials for myelofibrosis.
Arora S, Vachhani P, Bose P Expert Opin Investig Drugs. 2024; 33(12):1231-1244.
PMID: 39604120 PMC: 11669310. DOI: 10.1080/13543784.2024.2434696.
Treatment Strategies Used in Treating Myelofibrosis: State of the Art.
Martino M, Pitea M, Sgarlata A, Delfino I, Cogliandro F, Scopelliti A Hematol Rep. 2024; 16(4):698-713.
PMID: 39584924 PMC: 11587016. DOI: 10.3390/hematolrep16040067.